Kymera Therapeutics KYMR Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's additional paid-in capital?
- Kymera Therapeutics (KYMR) reported additional paid-in capital of $2.68B in Q1 2026.
- How has Kymera Therapeutics's additional paid-in capital changed year-over-year?
- Kymera Therapeutics's additional paid-in capital increased by 66.8% year-over-year, from $1.61B to $2.68B.
- What is the long-term trend for Kymera Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Kymera Therapeutics's additional paid-in capital has grown at a 45.0% compound annual growth rate (CAGR), from $412.78M to $2.64B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.